Cerevance
is a Massachusetts-based biotechnology company that researches and develops novel therapeutics for the treatment of neurological and psychiatric diseases... Read moreCerevance
is a Massachusetts-based biotechnology company that researches and develops novel therapeutics for the treatment of neurological and psychiatric diseases... Read more
News
Apr 08, 2025
GlobalNewswire
Press Release: Cerevance : Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting
Apr 02, 2025
Clinical Trials Arena
Cerevance: Cerevance to proceed with Phase III Parkinson's trial despite Phase II setback
Apr 01, 2025
Life Care News
Cerevance: Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinsons Disease at AD/PD 2025
Mar 27, 2025
Benzinga
Cerevance: New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson's Disease and Deep Pipeline for CNS-based Disorders
Nov 12, 2024
Clinical Trials Arena
Cerevance: Cerevance reports results from trial of CVN293 for neurodegenerative conditions
Nov 11, 2024
StreetInsider
Press Release: Cerevance : Cerevance's CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
Oct 08, 2024
Benzinga
Cerevance: Cerevance Achieves Second Milestone in Research Collaboration with Merck
Sep 23, 2024
Benzinga
Cerevance: Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
Jun 18, 2024
Benzinga
Cerevance: Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
May 20, 2024
GlobeNewswire
Press Release: Cerevance : Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
Cerevance Competitors
1
2
3
4
5
6
7
8
9
10